来氟米特治疗难治性原发性肾病疗效观察  

To Observe the Efficacy of Leflunomide in the Treatment of Refractory Nephrotic Syndrome

作　　者：刘金凤[1] 王满响[1] 王振[2] 

机构地区：[1]沭阳县人民医院肾内科,沭阳223600 [2]佳木斯大学附属第一临床医院,佳木斯154000

出　　处：《航空航天医学杂志》2012年第11期1288-1290,共3页Journal of Aerospace medicine

摘　　要：目的:探讨来氟米特在难治性肾病治疗中的有效性、安全性及耐受性。方法:根据患者意愿及经济情况,将难治性肾病78例患者分为治疗组来氟米特(26例)组,对照1组吗替麦考酚酯(26例)组和对照2组环磷酰胺(26例)组,随访观察其疗效及不良反应情况。结果:来氟米特组治疗有效23例(88.4%),吗替麦考酚酯组有效23例(93.3%),环磷酰胺组有效18例(69.2%)。来氟米特组与吗替麦考酚组有效率比较差异无统计学意义(P>0.05)。来氟米特组与环磷酰胺组有效率比较差异有统计学意义(P<0.05),患者药物不良反应少见,能耐受,来氟米特更经济,实惠,适合贫困地区。结论:来氟米特治疗难治性肾病有效、安全,患者能够耐受。Objective ：To investigate the effect of leflunomide in the treatment of refractory nephrotic syndrome efficacy, safety and tolerability. Methods：According to the willingness of patients and the economic situation, the refractory ne- phrotic syndrome in 78cases of patients were divided into the treatment group of leflunomide （26） group, control group 1, myeophenolate mofetil （26） and control group 2eyclophosphamide （26） group, follow up observation of its curative effect and adverse reaction. Results：The results of leflunomide in group treatment effectiveness in 23 cases （88.4%）, mycophenolate mofetil group effectiveness in 23 cases （93.3%）, eyclophosphamide group effectiveness in 18 cases （69. 2% ） . Contract with mycophenolate mofetil atel, the efficacy of on treating Refractory nephropathy leflunomide was no statistical difference （ P 〉 0. 05 ）. Leflunomide and eyclophosphamide group rate had a statistical difference （ P 〈 0. 05 ）, patients with adverse drug reactions were mild, leflunomide more economic, affordable for poverty. Conclusions ： leflunomide is safe and effective medicine in treating refractory nephrotie, patients can tolerate.

关 键 词：难治性肾病 药物疗法 来氟米特 

分 类 号：R692[医药卫生—泌尿科学]